Physician profile
Kelly Meier
NPI 1073733069
$2,525.63
in general payments reported to CMS, 2019-2025
30 companies · $363 in 2025
The $363 reported for 2025 was more than what 87% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $364 · 2021: $491 · 2022: $446 · 2023: $404 · 2024: $240 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $449.23 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $277.50 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $270.53 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $253.46 | 2020-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $176.86 | 2021-2023 | Qelbree |
| Glaxosmithkline, LLC. | $159.34 | 2019-2025 | Bexsero |
| Sanofi Pasteur INC. | $101.88 | 2021-2025 | |
| Pfizer INC. | $97.47 | 2020-2024 | |
| Neos Therapeutics, LP | $88.99 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.77 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $70.53 | 2025 | Jornay Pm |
| Daiichi Sankyo INC. | $56.11 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $55.17 | 2021-2023 | |
| Sobi, INC | $54.70 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $36.91 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $36.61 | 2020 | |
| Hologic Sales and Service, LLC | $33.08 | 2023-2024 | Aptima, Third Wave |
| Ironwood Pharmaceuticals, INC | $29.94 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $22.27 | 2023 | Flumist Quadrivalent |
| Alk-Abello, INC | $21.93 | 2024 | Odactra, Ragwitek, Grastek |
| Abbvie INC. | $18.89 | 2021 | |
| Genzyme Corporation | $17.64 | 2021 | |
| Kyowa Kirin, INC. | $15.45 | 2024 | Crysvita |
| Exeltis, USA INC. | $15.44 | 2025 | Slynd |
| Novartis Pharmaceuticals Corporation | $15.29 | 2019 | |
| Shire North American Group INC | $13.67 | 2019 | |
| Biomarin Pharmaceutical INC. | $13.51 | 2024 | Voxzogo 1.2mg |
| Neurelis, INC. | $13.02 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.88 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.